FDA Inspection 1265199 — APIPHARMA D.O.O

APIPHARMA D.O.O — FEI 3010235999

The FDA completed an inspection of APIPHARMA D.O.O on Mar 28, 2025 in Nasice. The inspection was classified OAI (Official Action Indicated — regulatory and/or administrative actions are recommended). 10 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI)
End Date
Mar 28, 2025
Fiscal Year
2025
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Nasice (Croatia)

Citations

IDCFRDescription
109821 CFR 211.22(c)Approve or reject procedures or specs
136121 CFR 211.100(a)Absence of Written Procedures
139521 CFR 211.103Actual vs. theoretical yields not determined
144821 CFR 211.111Establishment of time limitations
188321 CFR 211.165(a)Testing and release for distribution
202721 CFR 211.192Investigations of discrepancies, failures
360321 CFR 211.160(b)Scientifically sound laboratory controls
361121 CFR 211.160(b)(3)Acceptance of drug products
363221 CFR 211.170(b)Annual visual exams of drug products
435721 CFR 211.166(a)Results not used for expiration dates, storage cond.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.